Form D · Biotechnology
3Helix, Inc.
Salt Lake City, UT · CIK 0002001622
Offering snapshot reported Sep 21, 2026 · SEC filing
- Reported sold
- $7.84M Offering amount: $10M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2026 | Initial | $7,835,028 | No comparison | 13 | SEC filing |
| Nov 29, 2023 | Initial | $3,749,987 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598179
Source: Form D, filed Sep 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Fugman | Director |
| Nalini D Kelly | Director |
| Michael Kirkness | Director, Executive |
| Noah Nasser | Director |
| Michael Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
650 Komas, Suite 202
Salt Lake City, UT, 84108
Phone: 778 858 1952
Salt Lake City, UT, 84108
Phone: 778 858 1952